Continuous Renal Replacement Therapy Market

Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region - Global Forecast to 2028

Report Code: MD 3842 Oct, 2023, by marketsandmarkets.com

The global continuous renal replacement therapy market in terms of revenue was estimated to be worth $1.4 billion by 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 8.1% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Various factors such as rise in worldwide prevalence of AKI, Growing number of ICU patients with AKI and rising incidences of sepsis, and growing clinical advantage of CRRT over intermittent blood purification are factors likely to accelerate the growth of the market. Moreover, presence of well-established key players focusing on developing and commercializing technologically advanced and initiatives undertaken by government to increase the awareness about CRRT are likely to propel the market growth during the forecast period.

Attractive opportunities CRRT Market

Continuous Renal Replacement Therapy Market

To know about the assumptions considered for the study, Request for Free Sample Report

Continuous Renal Replacement Therapy Market

Continuous Renal Replacement Therapy Market Dynamics

Driver: Increase in the prevalence of incidence of acute kidney injury (AKI)

, The primary factor of the market growth is increasing incidences of Acute kidney injury which is, expected to boost the demand for CRRT. For instance , according to the International Society of Nephrology(INR), an estimation of 13.3 million cases of AKI were registered annually worldwide. This is anticipated to boost the adoption of continuous renal replacement therapy at a higherrate. With the increase in the geriatric population globally, the prevalence of kidney-related diseases is expected to grow significantly. This, in turn, is expected to attribute to the growth of the CRRT market at a significant rate during the forecast period.

Restraint: High procedural cost of CRRT

As the population in emerging nations is price-sensitive, they prefer lower-priced products. Although the cost of CRRT in developing countries is high which makes these procedures are still unaffordable for a large portion of the population due to the low purchasing power. This limits the demand and uptake of CRRT in developing as well as developed countries. Because of the high regulatory barriers, number of CRRT products that are approved in other countries have yet to be approved by the FDA. The share of the US in the global CRRT market is mainly due to its large population base of the acute kidney injury (AKI). Hence, the presence of stringent and time-consuming regulatory policies for the approval of new CRRT products in the region poses restraint to the growth of the global CRRT market.

Opportunity: Emerging markets in APAC and RoW

In the Asia Pacific region, China, India, Japan, and South Korea are a few of the major markets for CRRT. The demand for CRRT is being driven by a sharp rise in the number of AKI cases in these nations. Furthermore, the governments of these nations are spending a lot of money on healthcare infrastructure, which is accelerating the expansion of the CRRT market.. Additionally, regulatory policies in the Asia Pacific region are more adaptive and less-stringent. This, along with the increasing competition in the mature markets (Europe, Japan, and Australia), will further boost up the growth of CRRT market in Asia pacific region.

Challenge: Shortage of trained ICU professionals in developing nations

CRRT is a one of the specialized and critical therapy which involves complex nursing care. Precise training of ICU nurses are required for the continuous assessment of indications, ensuring good vascular access, , and prevention of complications in patients during CRRT. Although , currently, there is a lack of registered nurses in ICU settings. Moreover the complexity associated with CRRT are likely to hamper the market growth.

Ecosystem Analysis

The ecosystem map of the overall leukapheresis market comprises the elements present in this market and defines these elements with a demonstration of the bodies involved. CRRT products include systems and disposables. These products vary based on:

  • Different types, including dialysates and replacement fluids, disposables and CRRT systems.

Disposables, including Hemofilters, Blood line and tubes and other disposables

Continuous Renal Replacement Therapy Market Ecosystem

By product, dialysates & replacement fluid segment of the continuous renal replacement therapy industry is to capture largest market share during the forecast period.

The largest share of this segment of the continuous renal replacement therapy market is attributed to factors such growing demand for dialysates to remove undesired solutes and restoring the electrolytes and acid-base balance in the blood along with presence of well established players with strong offerings in dialysates & replacement fluid. The dialysates and replacement fluids helps in removing undesired solutes and restores the electrolytes and acid-base balance in the blood. The CRRT procedures utilizes the lactate-buffered solutions or sterilized bicarbonate-buffered solutions as replacement fluids. The consumption of these fluids varies with different CRRT modalities, Hence it is more accurate and convenient to use.

The continuous venovenous hemodiafiltration (CVVHDF) is witnessed to have highest growth rate of the continuous renal replacement therapy industry, by modality during the forecast period.

The high growth rate of the CVVHDF segment can be attributed to its flexibility as compared to other CRRT modalities. The CVVHDF modality also combines the benefits of convection and diffusion for the removal of solutes, which is another major factor supporting its growth. The CVVHDF approach is more effective for the removal of small to medium-sized molecules. This therapy is used in patients with fluid overload, congestive heart failure, and acute renal failure.

Adult segment accounted for the largest share of the continuous renal replacement therapy industry, by age group, in 2022

The increasing demand for invisible braces among adults due to large adult population base with AKI, increase in the hospitalization among adult population, and the large availability of CRRT system and disposables for adults undergoing CRRT procedure. The adult population is the fastest-growing age group in both developed and developing nations. It has resulted in the increasing frequency of aggressive surgical and medical interventions, increasing the risk of developing AKI and further contributing to the market growth.

Continuous Renal Replacement Therapy Market by Region

To know about the assumptions considered for the study, download the pdf brochure

North America is projected to be the largest regional market for continuous renal replacement therapy industry

North America dominates continuous renal replacement therapy market. The north American region is gaining traction with the increasing incidence and prevalence of AKI. Moreover due to strong foothold of major key players in the region, rising approval of CRRT products for multiple application across many countries, and initiatives by government to increase the awareness about the advancements in renal therapy are likely to play a major role in fueling the growth of the CRRT market in North America.

The prominent players operating in the global continuous renal replacement therapy market include Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), and B. Braun Melsungen AG (Germany),

Scope of the Continuous Renal Replacement Therapy Industry:

Report Metric

Details

Market Revenue in 2023

$1.4 billion

Estimated Value by 2028

$2.1 billion

Revenue Rate

Poised to grow at a CAGR of 8.1%

Market Driver

Increase in the prevalence of incidence of acute kidney injury (AKI)

Market Opportunity

Emerging markets in APAC and RoW

This research report categorizes the Continuous Renal Replacement Therapy Market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Dialysates and Replacement Fluids
  • Disposables
  • Hemofilters
  • Bloodline Sets & Tubes
  • Other Disposables
  • CRRT Systems

By Modality

  • Continuous venovenous hemofiltration (CVVH)
  • Continuous venovenous hemodiafiltration (CVVHDF)
  • Continuous venovenous haemodialysis (CVVHD)
  • Slow continuous ultrafiltration (SCUF)

By Age Group

  • Adults
  • Pediatrics /Neonates

By End User

  • Hospital
  • Ambulatory care
  • Homecare
  • Others

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • RoEU
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments of Continuous Renal Replacement Therapy Industry

  • In 2020, Medtronic plc announced the launch of the Carpediem system, the first and only pediatric and neonatal acute dialysis system designed to treat patients weighing 2.5–10 kg (5.5–22 pounds) requiring renal replacement therapy.
  • In 2019, Baxter International Inc. introduced the PrisMax CRRT system in the US
  • In 2019, Fresenius Medical Care AG & CO. KGaA announced the launch of the 4008A dialysis machine in India.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 31)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: REGIONAL SEGMENTATION
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY 
    1.5 MAJOR MARKET STAKEHOLDERS 
    1.6 SUMMARY OF CHANGES 
    1.7 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Insights from industry experts
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARIES: CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET
                                FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 7 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
          FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: BAXTER INTERNATIONAL INC.
          FIGURE 9 REVENUE SHARE ANALYSIS FOR TOP PLAYERS
          FIGURE 10 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
          FIGURE 11 DEMAND-SIDE MARKET ESTIMATION: CONTINUOUS RENAL REPLACEMENT THERAPY CONSUMABLES
          FIGURE 12 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN MARKET (2023–2028)
          FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
          FIGURE 14 TOP-DOWN APPROACH
    2.3 DATA TRIANGULATION 
          FIGURE 15 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH ASSUMPTIONS 
    2.5 RISK ASSESSMENT 
          TABLE 1 RISK ASSESSMENT: MARKET
    2.6 LIMITATIONS 
    2.7 METHODOLOGY-RELATED LIMITATIONS 
    2.8 RECESSION IMPACT 
 
3 EXECUTIVE SUMMARY (Page No. - 50)
    FIGURE 16 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 17 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY MODALITY, 2023 VS. 2028 (USD MILLION)
    FIGURE 18 MARKET, BY AGE GROUP, 2023 VS. 2028 (USD MILLION)
    FIGURE 19 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 20 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW 
          FIGURE 21 RISING PREVALENCE OF ACUTE KIDNEY INJURY AND GROWING AWARENESS OF CRRT TO DRIVE MARKET
    4.2 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT AND COUNTRY (2022) 
          FIGURE 22 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022
    4.3 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 23 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
    4.4 REGIONAL MIX: MARKET (2021–2028) 
          FIGURE 24 NORTH AMERICA WILL CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD
    4.5 MARKET: EMERGING VS. DEVELOPED MARKETS 
          FIGURE 25 EMERGING MARKETS TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 58)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 26 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing incidence of acute kidney injury (AKI)
                                FIGURE 27 GLOBAL INCIDENCE OF ACUTE KIDNEY INJURY, 2010 VS. 2015 VS. 2020
                                TABLE 2 NUMBER OF PEOPLE AGED 65 OR OVER, BY REGION, 2019 VS. 2050
                    5.2.1.2 Growing number of ICU patients with AKI and increasing incidence of sepsis
                                FIGURE 28 IMPACT OF ICU-ACQUIRED AKI IN US
                    5.2.1.3 Increasing clinical advantage of CRRT over intermittent blood purification
                    5.2.1.4 Technological advancements and new product launches
                    5.2.1.5 Growing prevalence of diabetes and hypertension
           5.2.2 RESTRAINTS
                    5.2.2.1 Stringent regulatory guidelines in North America
                    5.2.2.2 High procedural cost of CRRT
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets in Asia Pacific and RoW
                    5.2.3.2 Increasing applications of CRRT
                               5.2.3.2.1 Evolution of CRRT from simple renal replacement treatment to multi-organ support therapy
                               5.2.3.2.2 Progression of CRRT from adaptive renal devices to multipurpose treatment machines
                    5.2.3.3 Ongoing research to establish safety and efficacy profile of CRRT
                    5.2.3.4 Development of CRRT systems for pediatric patients
                               5.2.3.4.1 The CARPEDIEM Project
                    5.2.3.5 Untapped growth opportunities in North America
           5.2.4 CHALLENGES
                    5.2.4.1 High complexity of CRRT
                    5.2.4.2 Lack of standard treatment guidelines in developing nations
                    5.2.4.3 Shortage of trained ICU professionals in developing nations
                    5.2.4.4 Poor reimbursement scenario in developing countries
                    5.2.4.5 Lack of awareness about benefits of CRRT
    5.3 REGULATORY ANALYSIS 
           5.3.1 NORTH AMERICA
           5.3.2 EUROPE
           5.3.3 ASIA PACIFIC
                    5.3.3.1 India
                    5.3.3.2 China
                    5.3.3.3 Japan
                    5.3.3.4 South Korea
           5.3.4 REST OF THE WORLD (ROW)
                    5.3.4.1 Brazil
                    5.3.4.2 Argentina
    5.4 REIMBURSEMENT SCENARIO 
           5.4.1 NORTH AMERICA
           5.4.2 EUROPE
           5.4.3 ASIA PACIFIC
                    5.4.3.1 Japan
           5.4.4 REST OF THE WORLD (ROW)
                    5.4.4.1 Brazil
                    5.4.4.2 Central America and the Caribbean
    5.5 KEY CONFERENCES & EVENTS 
          TABLE 3 KEY CONFERENCES & EVENTS, 2023
    5.6 PATENT ANALYSIS 
           5.6.1 PATENT PUBLICATION TRENDS FOR CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
                    FIGURE 29 PATENT PUBLICATION TRENDS (JANUARY 2013–AUGUST 2023)
           5.6.2 INSIGHTS ON JURISDICTION AND TOP APPLICANT ANALYSIS
                    FIGURE 30 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
                    FIGURE 31 TOP 10 APPLICANT COUNTRIES/REGIONS FOR CONTINUOUS RENAL REPLACEMENT PATENTS, 2013–2023
                    TABLE 4 MARKET: LIST OF MAJOR PATENTS
    5.7 TRADE ANALYSIS 
    5.8 TECHNOLOGY ANALYSIS 
           5.8.1 MINIMALLY INVASIVE CRRT
           5.8.2 CRRT IN COMBINATION WITH OTHER THERAPIES
    5.9 ECOSYSTEM ANALYSIS 
    5.10 VALUE CHAIN ANALYSIS 
           FIGURE 32 VALUE CHAIN OF MARKET
    5.11 PRICING TREND ANALYSIS 
           TABLE 5 AVERAGE PRICE OF CRRT SYSTEMS AND CONSUMABLES, BY COUNTRY, 2020 (USD)
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 6 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MARKET
                     TABLE 7 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MARKET
           5.13.2 BUYING CRITERIA
                     FIGURE 34 KEY BUYING CRITERIA FOR MARKET
                     TABLE 8 KEY BUYING CRITERIA FOR MARKET
    5.14 ARTIFICIAL INTELLIGENCE INTEGRATION IN CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 
    5.15 UNMET NEED & END-USER EXPECTATIONS WITH CONTINUOUS RENAL REPLACEMENT THERAPY SYSTEMS 
 
6 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT (Page No. - 85)
    6.1 INTRODUCTION 
          TABLE 9 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 DIALYSATE & REPLACEMENT FLUIDS 
           6.2.1 RISING DEMAND FOR DIALYSATE TO DRIVE MARKET
                    TABLE 10 DIALYSATE & REPLACEMENT FLUIDS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 DISPOSABLES 
          TABLE 11 DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 12 DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.1 HEMOFILTERS
                    6.3.1.1 Widely adopted during CRRT procedures for treatment of AKI
                                 TABLE 13 HEMOFILTERS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.2 BLOODLINE SETS & TUBES
                    6.3.2.1 Development of blood tubing with special coding to prevent clotting to offer growth opportunities
                                 TABLE 14 BLOODLINE SETS & TUBES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 OTHER DISPOSABLES
                    TABLE 15 OTHER DISPOSABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 CRRT SYSTEMS 
           6.4.1 AVAILABILITY OF TECHNOLOGICALLY ADVANCED, EASY-TO-USE SYSTEMS TO BOOST MARKET GROWTH
                    TABLE 16 CRRT SYSTEMS MARKET BY COUNTRY, 2021–2028 (USD MILLION)
 
7 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY MODALITY (Page No. - 94)
    7.1 INTRODUCTION 
          TABLE 17 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY MODALITY, 2021–2028 (USD MILLION)
    7.2 CONTINUOUS VENOVENOUS HEMOFILTRATION 
           7.2.1 WIDESPREAD ADOPTION IN TREATMENT OF ACUTE KIDNEY INJURY TO DRIVE MARKET
                    TABLE 18 CONTINUOUS VENOVENOUS HEMOFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION 
           7.3.1 USED IN PATIENTS WITH CONGESTIVE HEART FAILURE
                    TABLE 19 CONTINUOUS VENOVENOUS HEMODIAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 CONTINUOUS VENOVENOUS HEMODIALYSIS 
           7.4.1 MORE EFFECTIVE IN REMOVING SMALL TO MEDIUM-SIZED MOLECULES COMPARED TO OTHER CRRT MODALITIES
                    TABLE 20 CONTINUOUS VENOVENOUS HEMODIALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.5 SLOW CONTINUOUS ULTRAFILTRATION 
           7.5.1 DOES NOT USE DIALYSATE OR REPLACEMENT FLUIDS FOR REMOVAL OF EXCESS FLUID FROM BLOODSTREAM
                    TABLE 21 SLOW CONTINUOUS ULTRAFILTRATION MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY AGE GROUP (Page No. - 101)
    8.1 INTRODUCTION 
          TABLE 22 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY AGE GROUP, 2021–2028 (USD MILLION)
    8.2 ADULTS 
           8.2.1 LARGEST AND FASTEST-GROWING SEGMENT OF MARKET
                    TABLE 23 MARKET FOR ADULTS, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 PEDIATRICS & NEONATES 
           8.3.1 HIGH PREVALENCE OF AKI IN NEONATES TO SUPPORT MARKET GROWTH
                    TABLE 24 MARKET FOR PEDIATRICS & NEONATES, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY END USER (Page No. - 105)
    9.1 INTRODUCTION 
          TABLE 25 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    9.2 HOSPITALS 
           9.2.1 FASTEST-GROWING END-USER SEGMENT
                    TABLE 26 MARKET FOR HOSPITALS, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 AMBULATORY CARE 
           9.3.1 REDUCED INPATIENT STAY TO SUPPORT MARKET GROWTH
                    TABLE 27 MARKET FOR AMBULATORY CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 HOME CARE 
           9.4.1 RISING ADOPTION OF PORTABLE AND HOME-BASED DEVICES TO AID MARKET GROWTH
                    TABLE 28 MARKET FOR HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    9.5 OTHER END USERS 
          TABLE 29 MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY REGION (Page No. - 111)
     10.1 INTRODUCTION 
             TABLE 30 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             10.2.1 NORTH AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        FIGURE 35 NORTH AMERICA: MARKET SNAPSHOT
                        TABLE 31 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 32 NORTH AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 33 NORTH AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 34 NORTH AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 35 NORTH AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 36 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Large number of AKI patients to drive market
                                      TABLE 37 US: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 38 US: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 39 US: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 40 US: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 41 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 High cost of CRRT to negatively impact market growth
                                      TABLE 42 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 43 CANADA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 44 CANADA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 45 CANADA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 46 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPEAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 47 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 48 EUROPE: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 49 EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 50 EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 51 EUROPE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 52 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Largest market for continuous renal replacement therapy in Europe
                                      TABLE 53 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 54 GERMANY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 55 GERMANY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 56 GERMANY: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 57 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Rising number of sepsis cases to support market growth
                                      TABLE 58 UK: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 59 UK: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 60 UK: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 61 UK: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 62 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Growing AKI patient population to propel market growth
                                      TABLE 63 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 64 FRANCE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 65 FRANCE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 66 FRANCE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 67 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Government initiatives to promote awareness of renal care to drive market
                                      TABLE 68 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 69 ITALY: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 70 ITALY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 71 ITALY: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 72 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Favorable reimbursement scenario to favor market growth
                                      TABLE 73 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 74 SPAIN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 75 SPAIN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 76 SPAIN: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 77 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                        TABLE 78 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 79 REST OF EUROPE: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 80 REST OF EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 81 REST OF EUROPE: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 82 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             10.4.1 ASIA PACIFIC CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        FIGURE 36 ASIA PACIFIC: MARKET SNAPSHOT
                        TABLE 83 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 84 ASIA PACIFIC: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 85 ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 86 ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 87 ASIA PACIFIC: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 88 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Well-established medical infrastructure to support market growth
                                      TABLE 89 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 90 JAPAN: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 91 JAPAN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 92 JAPAN: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 93 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 CHINA
                        10.4.3.1 Increasing prevalence of ESRD and AKI to boost demand for CRRT
                                      TABLE 94 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 95 CHINA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 96 CHINA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 97 CHINA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 98 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Large patient population to support market growth
                                      TABLE 99 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 100 INDIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 101 INDIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 102 INDIA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 103 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 AUSTRALIA
                        10.4.5.1 Government initiatives to increase adoption of CRRT
                                      TABLE 104 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 105 AUSTRALIA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 106 AUSTRALIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 107 AUSTRALIA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 108 AUSTRALIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.6 SOUTH KOREA
                        10.4.6.1 Increasing awareness through online education programs and events to aid market growth
                                      TABLE 109 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 110 SOUTH KOREA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 111 SOUTH KOREA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 112 SOUTH KOREA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 113 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.7 REST OF ASIA PACIFIC
                        TABLE 114 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 115 REST OF ASIA PACIFIC: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 116 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 117 REST OF ASIA PACIFIC: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 118 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LATIN AMERICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 119 LATIN AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 120 LATIN AMERICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 121 LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 122 LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 123 LATIN AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 124 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 BRAZIL
                        10.5.2.1 Rising incidence of AKI to drive market
                                      TABLE 125 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 126 BRAZIL: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 127 BRAZIL: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 128 BRAZIL: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 129 BRAZIL: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 MEXICO
                        10.5.3.1 Large patient population to drive market
                                      TABLE 130 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 131 MEXICO: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 132 MEXICO: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 133 MEXICO: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                                      TABLE 134 MEXICO: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.4 REST OF LATIN AMERICA
                        TABLE 135 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 136 REST OF LATIN AMERICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 137 REST OF LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 138 REST OF LATIN AMERICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 139 REST OF LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 LACK OF AWARENESS REGARDING CRRT TO RESTRAIN MARKET GROWTH
             10.6.2 MIDDLE EAST AND AFRICAN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET: RECESSION IMPACT
                        TABLE 140 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 141 MIDDLE EAST & AFRICA: CONTINUOUS RENAL REPLACEMENT THERAPY DISPOSABLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 142 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                        TABLE 143 MIDDLE EAST & AFRICA: MARKET, BY AGE GROUP, 2021–2028 (USD MILLION)
                        TABLE 144 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 166)
     11.1 OVERVIEW 
             FIGURE 37 GROWTH STRATEGIES ADOPTED BY KEY PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY MARKET
     11.2 REVENUE SHARE ANALYSIS OF MARKET PLAYERS, 2018–2022 (USD MILLION) 
             FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY
             FIGURE 39 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022
             TABLE 145 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: DEGREE OF COMPETITION
     11.3 COMPANY EVALUATION MATRIX 
             11.3.1 STARS
             11.3.2 EMERGING LEADERS
             11.3.3 PERVASIVE PLAYERS
             11.3.4 PARTICIPANTS
                        FIGURE 40 CONTINUOUS RENAL REPLACEMENT THERAPY INDUSTRY: COMPANY EVALUATION MATRIX, 2022
     11.4 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 
             11.4.1 PROGRESSIVE COMPANIES
             11.4.2 STARTING BLOCKS
             11.4.3 RESPONSIVE COMPANIES
             11.4.4 DYNAMIC COMPANIES
                        FIGURE 41 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
     11.5 FOOTPRINT ANALYSIS OF PLAYERS IN MARKET 
             TABLE 146 PRODUCT, REGIONAL, AND END-USER FOOTPRINT ANALYSIS OF PLAYERS IN MARKET
             TABLE 147 PRODUCT FOOTPRINT OF COMPANIES
             TABLE 148 END-USER FOOTPRINT OF COMPANIES
             TABLE 149 REGIONAL FOOTPRINT OF COMPANIES
     11.6 MARKET: PRODUCT LAUNCHES AND REGULATORY APPROVALS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 150 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
     11.7 MARKET: DEALS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 151 KEY DEALS
     11.8 MARKET: OTHER DEVELOPMENTS (JANUARY 2019 TO AUGUST 2023) 
             TABLE 152 OTHER KEY DEVELOPMENTS
 
12 COMPANY PROFILES (Page No. - 180)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
     12.1 MAJOR PLAYERS 
             12.1.1 BAXTER INTERNATIONAL, INC.
                        TABLE 153 BAXTER INTERNATIONAL, INC.: BUSINESS OVERVIEW
                        FIGURE 42 BAXTER INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022)
                        TABLE 154 BAXTER INTERNATIONAL, INC.: PRODUCT OFFERINGS
             12.1.2 FRESENIUS MEDICAL CARE AG & CO. KGAA
                        TABLE 155 FRESENIUS MEDICAL CARE AG & CO. KGAA: BUSINESS OVERVIEW
                        FIGURE 43 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT (2022)
                        TABLE 156 FRESENIUS MEDICAL CARE AG & CO. KGAA: PRODUCT OFFERINGS
             12.1.3 NIKKISO CO., LTD.
                        TABLE 157 NIKKISO CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 44 NIKKISO CO., LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 158 NIKKISO CO., LTD.: PRODUCT OFFERINGS
             12.1.4 B. BRAUN MELSUNGEN AG
                        TABLE 159 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                        FIGURE 45 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2022)
                        TABLE 160 B. BRAUN MELSUNGEN AG: PRODUCT OFFERINGS
             12.1.5 MEDTRONIC PLC
                        TABLE 161 MEDTRONIC PLC: BUSINESS OVERVIEW
                        FIGURE 46 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
                        TABLE 162 MEDTRONIC PLC: PRODUCT OFFERINGS
             12.1.6 ASAHI KASEI CORPORATION
                        TABLE 163 ASAHI KASEI CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 164 ASAHI KASEI CORPORATION: PRODUCT OFFERINGS
             12.1.7 TORAY MEDICAL CO., LTD.
                        TABLE 165 TORAY MEDICAL CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 48 TORAY MEDICAL CO., LTD.: COMPANY SNAPSHOT (2022)
                        TABLE 166 TORAY MEDICAL CO., LTD.: PRODUCT OFFERINGS
             12.1.8 NIPRO CORPORATION
                        TABLE 167 NIPRO CORPORATION: BUSINESS OVERVIEW
                        FIGURE 49 NIPRO CORPORATION: COMPANY SNAPSHOT (2022)
                        TABLE 168 NIPRO CORPORATION: PRODUCT OFFERINGS
             12.1.9 INFOMED SA
                        TABLE 169 INFOMED SA: BUSINESS OVERVIEW
                        TABLE 170 INFOMED SA: PRODUCT OFFERINGS
             12.1.10 MEDICA SPA
                        TABLE 171 MEDICA SPA: BUSINESS OVERVIEW
                        TABLE 172 MEDICA SPA: PRODUCT OFFERINGS
             12.1.11 MEDITES PHARMA SPOL. S.R.O.
                        TABLE 173 MEDITES PHARMA SPOL. S.R.O.: BUSINESS OVERVIEW
                        TABLE 174 MEDITES PHARMA SPOL. S.R.O.: PRODUCT OFFERINGS
             12.1.12 MEDICAL COMPONENTS, INC.
                        TABLE 175 MEDICAL COMPONENTS, INC.: BUSINESS OVERVIEW
                        TABLE 176 MEDICAL COMPONENTS, INC.: PRODUCT OFFERINGS
             12.1.13 SWS HEMODIALYSIS CARE CO., LTD.
                        TABLE 177 SWS HEMODIALYSIS CARE CO., LTD.: BUSINESS OVERVIEW
                        TABLE 178 SWS HEMODIALYSIS CARE CO., LTD.: PRODUCT OFFERINGS
             12.1.14 NINGBO TIANYI MEDICAL DEVICES CO., LTD.
                        TABLE 179 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: BUSINESS OVERVIEW
                        TABLE 180 NINGBO TIANYI MEDICAL DEVICES CO., LTD.: PRODUCT OFFERINGS
             12.1.15 ANJUE MEDICAL EQUIPMENT CO., LTD.
                        TABLE 181 ANJUE MEDICAL EQUIPMENT CO., LTD.: BUSINESS OVERVIEW
                        TABLE 182 ANJUE MEDICAL EQUIPMENT CO., LTD.: PRODUCT OFFERINGS
             12.1.16 KIMAL
                        TABLE 183 KIMAL: BUSINESS OVERVIEW
                        TABLE 184 KIMAL.: PRODUCT OFFERINGS
             12.1.17 JIANGXI SANXIN MEDTEC CO., LTD.
                        TABLE 185 JIANGXI SANXIAN MEDTECH CO., LTD.: BUSINESS OVERVIEW
                        TABLE 186 JIANGXI SANXIAN MEDTECH CO., LTD.: PRODUCT OFFERINGS
     12.2 OTHER PLAYERS 
             12.2.1 ALLMED MEDICAL PRODUCTS CO., LTD.
             12.2.2 DIALCO MEDICAL INC.
             12.2.3 BROWNDOVE HEALTHCARE PVT. LTD.
             12.2.4 STERIS PLC
             12.2.5 KURARAY MEDICAL PLC
             12.2.6 LIVANOVA PLC
             12.2.7 DIAVERUM DEUTSCHLAND GMBH
             12.2.8 SEMBCORP INDUSTRIES
 
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
 
13 APPENDIX (Page No. - 226)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

The study involved four major activities to estimate the current size of the Continuous Renal Replacement Therapy (CRRT) market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources, such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, regulatory bodies, and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), American Society Nephrology (ASN), American Association of Kidney Patients (AAKP), European Renal Association were referred to identify and collect information for the CRRTmarket study.

Primary Research

The CRRT market comprises several stakeholders such as manufacturers Of CRRT machine, CRRT disposables, dialysates and replacement fluids, market research and consulting firms. The demand side of this market is characterized by the increasing AKI, growing awareness of CRRT, and increased in number of players in the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is the breakdown of primary respondents:

Continuous Renal Replacement Therapy Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the CRRT market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Continuous Renal Replacement Therapy Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Continuous Renal Replacement Therapy Market Size, and Share

Data Triangulation

After arriving at the overall size of the global CRRT market through the above-mentioned methodology, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for the key segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand- and supply-side participants.

Market Definition

Continuous renal replacement therapy (CRRT) is a dialysis modality used to treat critically ill, hospitalised patients in intensive care units (ICUs) with acute kidney injury (AKI). It is designed to provide round the clock treatment for impaired renal function over an extended period. CRRT is one of the preferred treatment choice among nephrologists for the treatment of haemodynamically unstable AKI patients. It offers hemodynamic tolerance by slowly and efficiently removing solutes compared to other dialysis techniques such as intermittent hemodialysis (IHD) and sustained low effiicncy dialysis (SLED).

Key stakeholders

  • CRRT manufacturers, vendors, and distributors
  • Distributors, channel partners, and third-party suppliers
  • CRRT service providers
  • Renal research laboratories
  • Renal associations and organizations
  • Healthcare service providers (including hospitals, critical care centers, and dialysis centers)
  • Academic medical centers and universities
  • Business research and consulting service providers
  • Venture capitalists and other government funding organizations

Report Objectives

  • To define, describe, and forecast the global CRRT market on the basis of product, modality, age group and region.
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East & Africa
  • To profile the key market players and comprehensively analyze their market shares and core competencies2
  • To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global CRRT market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the global CRRT market report

Product Analysis

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top five global players.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5 OEMs)

Geographic Analysis

  • Further breakdown of the Rest of Europe CRRT market into Belgium, Austria,
  • Denmark, Greece, Poland, and Russia, among other countries
  • Further breakdown of the Rest of Asia Pacific CRRT market into New Zealand, Vietnam, Philippines, Singapore, Malaysia, Thailand, and Indonesia, among other countries
  • Further breakdown of the Rest of Latin America CRRT market into Argentina, and Colombia, among other countries.
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3842
Published ON
Oct, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Continuous Renal Replacement Therapy Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback